Guangdong Taienkang Pharmaceutical Co. Ltd (SHE:301263) — Market Cap & Net Worth
Market Cap & Net Worth: Guangdong Taienkang Pharmaceutical Co. Ltd (301263)
Guangdong Taienkang Pharmaceutical Co. Ltd (SHE:301263) has a market capitalization of $1.21 Billion (CN¥8.26 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #8108 globally and #1859 in its home market, demonstrating a -2.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangdong Taienkang Pharmaceutical Co. Ltd's stock price CN¥19.41 by its total outstanding shares 425497500 (425.50 Million). Also see total assets of Guangdong Taienkang Pharmaceutical Co. L for a full breakdown of the balance sheet.
Guangdong Taienkang Pharmaceutical Co. Ltd Market Cap History: 2022 to 2026
Guangdong Taienkang Pharmaceutical Co. Ltd's market capitalization history from 2022 to 2026. Data shows growth from $1.07 Billion to $1.21 Billion (1.56% CAGR). Also see Guangdong Taienkang Pharmaceutical Co. L (301263) cash conversion ratio for how efficiently the company converts equity into cash flow.
Guangdong Taienkang Pharmaceutical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangdong Taienkang Pharmaceutical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Guangdong Taienkang Pharmaceutical Co. L share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.67x
Guangdong Taienkang Pharmaceutical Co. Ltd's market cap is 2.67 times its annual revenue
Latest Price to Earnings (P/E) Ratio
63.04x
Guangdong Taienkang Pharmaceutical Co. Ltd's market cap is 63.04 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.07 Billion | $783.48 Million | $174.61 Million | 1.36x | 6.10x |
| 2023 | $996.13 Million | $760.79 Million | $160.20 Million | 1.31x | 6.22x |
| 2024 | $933.33 Million | $721.03 Million | $108.22 Million | 1.29x | 8.62x |
| 2025 | $1.81 Billion | $674.90 Million | $28.63 Million | 2.67x | 63.04x |
Competitor Companies of 301263 by Market Capitalization
Companies near Guangdong Taienkang Pharmaceutical Co. Ltd in the global market cap rankings as of September 19, 2026. Review 301263 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Guangdong Taienkang Pharmaceutical Co. Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Guangdong Taienkang Pharmaceutical Co. Ltd Historical Marketcap From 2022 to 2026
Between 2022 and today, Guangdong Taienkang Pharmaceutical Co. Ltd's market cap moved from $1.07 Billion to $ 1.21 Billion, with a yearly change of 1.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.21 Billion | -33.05% |
| 2025 | CN¥1.81 Billion | +93.40% |
| 2024 | CN¥933.33 Million | -6.30% |
| 2023 | CN¥996.13 Million | -6.49% |
| 2022 | CN¥1.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Guangdong Taienkang Pharmaceutical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.21 Billion USD |
| MoneyControl | $1.21 Billion USD |
| MarketWatch | $1.21 Billion USD |
| marketcap.company | $1.21 Billion USD |
| Reuters | $1.21 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangdong Taienkang Pharmaceutical Co. Ltd
Guangdong Taienkang Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers various products covering various therapeutic areas, including sexual health medicines, ophthalmic medicines, gastrointestinal medicines, Chinese patent medicines and external medicines, and sanitary materials in the… Read more